Amgen Inc's Deep Pipeline Offsets Some of the Price Risk

Amgen's high-quality pipeline offsets some of the sector-wide price risk.

Feb 11, 2014 at 6:30PM

Like so many other drug stocks today, Amgen's (NASDAQ:AMGN) shares are not obviously cheap. What Amgen does have going for it, though, is a deep late-stage pipeline that helps offset some of the clinical risk. If the company's cholesterol drug evolocumab stays on track and oncology trial results in 2014 are favorable, I could see these shares outperforming in what is already pricey real estate in the stock market.

Fourth quarter earnings mostly a non-event
As I have observed with other drug companies, earnings are a secondary concern to most Amgen investors right now, provided that there are no major bad surprises. Not only were there no bad surprises in the fourth quarter, the results were actually pretty clean. Revenue rose 13% and beat expectations by about 4%, helped at least in part by some inventory stocking. Margins were fine as well, as a shortfall in gross margin was offset by better opex and the company beat operating income expectations by about 6%. 

Evolocumab the featured player today
Wall Street has a knack for taking large, diverse drug companies like Amgen and reducing their prospects down to a single drug. Right now that is Amgen's PCSK9 inhibitor for cholesterol called evolocumab.

PCSK9 inhibitors are one of the highest-potential therapeutic drug classes on the market right now, as investors imagine years of multibillion dollar sales similar to the statins of the prior decade. Amgen is running basically neck and and neck with Sanofi (NYSE:SNY) (which has licensed its PCSK9 drug from Regeneron) to be first to market, though Pfizer (NYSE:PFE) is not that far behind, and several other companies (including Lilly) are developing PCKS9 antibodies as well.

Thus far, the competition between Sanofi and Amgen is too close to call. The data on evolocumab have been a little better in terms of LDL reduction (around 7% to 10% better), but Sanofi has generally been enrolling patients with higher baseline LDLs. It's also very important to note that comparing trials like this is tricky as they are not identical or head-to-head studies. Amgen is also trying to close the gap on ease of use with its own auto-injector device. I think it's also important to note that Amgen's drug is a wholly owned program; the economics on Sanofi's deal with Regeneron are demanding (to Sanofi) and pretty much require a blockbuster level of sales to really deliver good returns.

It is also important to consider Pfizer's development program. Pfizer is taking its drug (bococizumab) through some truly huge (22,000 patients) Phase III outcomes studies. It is unclear if such outcomes data will be required for approval, but it is likely that they will need to be near at hand when the FDA evaluates these drugs. In any event, by studying so many patients with a variety of risk factors, Pfizer may have an edge when it comes to marketing the drug and demonstrating to clinicians and payers that there is real value to its drug. Of course, if the data go the other way and show that the reductions in LDL don't come with a reduction in actual outcomes (heart attacks, death, etc.), that could hurt the entire class.

A deep pipeline with oncology and more
Amgen has taken a significant turn toward oncology, following in the steps of Pfizer and many other large pharmaceutical companies. While not the only move by any means, the acquisition of Onyx for over $10 billion is perhaps the most visible sign that Amgen views this as an important area. In the near term, the key to the Onyx deal will be in setting the drug Kyprolis apart from rivals sold by Celgene and Takeda in the myeloma space, including trials aimed at positioning the drug as a first-line therapy.

Beyond this, Amgen should be announcing data from two other significant oncology programs in the first half of 2014. Amgen will be reporting data on the oncolytic virus T-vec in metastatic melanoma, as well as Phase IIb data on blinatumomab in acute lymphoblastic leukemia

Outside of oncology, Amgen has a pipeline that includes drugs for osteoporosis, hyperparathyroidism, migraine, and a range of inflammatory conditions. Amgen is also developing a pipeline of biosimilars targeting multibillion dollar biologics.

The bottom line
Amgen looks expensive on the basis of an intrinsic value calculation that uses risk-adjusted sales estimates and free cash flows. I'm looking for long-term revenue growth of 3% and FCF growth of almost double that, both of which are in line with my expectations for Sanofi and ahead of what I expect from most other large drug companies like Pfizer.

While my intrinsic value estimate doesn't make it to Amgen's current $120 price (let alone above it), I wouldn't necessarily rush to sell. I do worry that pharma/biotech valuations are stretched, but Amgen's valuation within that world is actually somewhat low. I do have some concerns that investors in this sector will be unhappy once the music stops, but strong data and potential rerating could support Amgen's stock in 2014.

Amgen may have trouble keeping up with this stock in 2014...
There's a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.

Stephen D. Simpson, CFA has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.

Compare Brokers